Rain Therapeutics Inc., a startup planning a phase II test of an experimental small-molecule drug for people with EGFR and ErbB exon 20 insertion mutations in non-small-cell lung cancer, has closed a tranched $18.4 million series A round. The financing was led by Biotechnology Value Fund (BVF) and followed by Perceptive Advisors, Auckland Uniservices Ltd.'s Inventors Fund and other private investors. The series A round follows a $1 million convertible note financing the company completed in late-2017.